MBX Biosciences (MBX) risk factors
Item 1A of every MBX Biosciences, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors107 risks4 new2 dropped11 reworded
MBX reported widening net losses of $87.0 million in 2025 compared to $61.9 million in 2024, pushing its accumulated deficit to $224.5 million. The company added new risks covering capital raising constraints, third-party manufacturing supply chain disruptions from international trade and tariffs, and environmental, social, and governance compliance burdens.
Filed Mar 12, 2026 - FY2024 10-K risk factors105 risks
MBX Biosciences has incurred significant cumulative losses and net losses of $61.9 million for 2024 and $32.6 million for 2023. The company relies heavily on early-stage clinical candidates like canvuparatide and MBX 1416 requiring substantial additional funding. Operations face severe regulatory risks including unpredictable FDA approvals and specialized cold-chain logistics requirements.
Filed Mar 17, 2025